PPHM Share Price

Open 0.31 Change Price %
High 0.31 1 Day 0.00 0.00
Low 0.30 1 Week -0.01 -3.23
Close 0.30 1 Month 0.01 3.45
Volume 903751 1 Year -0.93 -75.61
52 Week High 1.31
52 Week Low 0.00
PPHM Important Levels
Resistance 2 0.31
Resistance 1 0.31
Pivot 0.30
Support 1 0.29
Support 2 0.29
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM)

PPHM Technical Analysis 5
As on 2nd Dec 2016 PPHM Share Price closed @ 0.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.48 & Strong Sell for SHORT-TERM with Stoploss of 0.35 we also expect STOCK to react on Following IMPORTANT LEVELS.
PPHM Target for December
1st Target up-side 0.33
2nd Target up-side 0.36
3rd Target up-side 0.38
1st Target down-side 0.27
2nd Target down-side 0.24
3rd Target down-side 0.22
PPHM Other Details
Segment EQ
Market Capital 78153800.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.peregrineinc.com
PPHM Address
PPHM
14282 Franklin Avenue
Tustin, CA 92780
United States
Phone: 714-508-6000
Fax: 714-838-5817
Interactive Technical Analysis Chart Peregrine Pharmaceuticals Inc. ( PPHM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Peregrine Pharmaceuticals Inc.
PPHM Business Profile
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. The Company is conducting three randomized Phase II trials for bavituximab in combination with standard chemotherapy for front and second-line non-small cell lung cancer and front-line pancreatic cancer. In addition to these company-sponsored trials for bavituximab, the Company has four investigator-sponsored trials looking at different treatment combinations and additional oncology indications.